RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope

To date, gene therapy with transiently derived lentivectors has been very successful to cure rare infant genetic diseases. However, transient manufacturing is unfeasible to treat adult malignancies because large vector lots are required. By contrast, stable manufacturing is the best option for high-...

Descripción completa

Detalles Bibliográficos
Autores principales: Marin, Virna, Stornaiuolo, Anna, Piovan, Claudia, Corna, Stefano, Bossi, Sergio, Pema, Monika, Giuliani, Erica, Scavullo, Cinzia, Zucchelli, Eleonora, Bordignon, Claudio, Rizzardi, Gian Paolo, Bovolenta, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863723/
https://www.ncbi.nlm.nih.gov/pubmed/27222840
http://dx.doi.org/10.1038/mtm.2016.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863723/
https://www.ncbi.nlm.nih.gov/pubmed/27222840
http://dx.doi.org/10.1038/mtm.2016.33

Ejemplares similares